StockNews.AI
IRIX
StockNews.AI
7 days

Iridex Reports Second Quarter 2025 Financial Results

1. IRIDEX reported $13.6 million revenue, 7% growth YoY. 2. Cyclo G6 product revenue remains flat at $3.3 million. 3. Operating expenses reduced by 28%, improving financial efficiency. 4. Net loss decreased to $1.0 million from $2.7 million YoY. 5. Management forecasts cash flow breakeven and positive EBITDA in 2025.

15m saved
Insight
Article

FAQ

Why Bullish?

IRIDEX demonstrates consistent revenue growth and improving cost efficiency, enhancing investor confidence. A similar trend led to positive stock performance in prior growth quarters.

How important is it?

The article highlights improving financial metrics that could motivate investor interest in IRIX. Positive revenue trends and reduced losses are crucial indicators of business health.

Why Short Term?

The immediate financial improvements and management guidance suggest potential short-term stock appreciation. Continued operational efficiency may further sustain this momentum in the near future.

Related Companies

ALRMAAPLGEJNJ
August 12, 2025 16:05 ET  | Source: IRIDEX Corporation MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended June 28, 2025. Second Quarter 2025 Financial Highlights Generated total revenue of $13.6 million, representing growth of 7% year-over-year and 14% sequential growth versus the first quarter of 2025Cyclo G6® product family revenue was $3.3 million, essentially flat year-over-year Sold 13,100 Cyclo G6 probes compared to 15,100 in the prior year quarterSold 35 Cyclo G6 Glaucoma Laser Systems compared to 28 in the prior year quarter Retina product revenue was $8.0 million, representing growth of 10% year-over-year growth and 21% sequential growth versus the first quarter of 2025Reduced operating expense by 28% compared to the prior year periodAchieved its third consecutive quarter of positive non-GAAP adjusted EBITDACash and cash equivalents as of June 28, 2025 were $6.8 million, a reduction of $0.4 million in the quarter. “Our second quarter results represent the transformational progress we are making on refocusing our business model to drive toward profitability," said Patrick Mercer, President and CEO. "For the third consecutive quarter, we have achieved year-over-year revenue growth, reduced operating expenses, and delivered breakeven or better adjusted EBITDA. We continue to identify and execute on additional opportunities to lower expenses further and improve margins. We remain focused and committed to take the necessary steps to build a more financially disciplined self-sustaining business, while strengthening our competitive position in the market.” Second Quarter 2025 Financial ResultsRevenue for the three months ended June 28, 2025 was $13.6 million, representing 7% year-over-year growth and 14% sequential growth versus the first quarter of 2025. Growth was driven primarily by higher Pascal system sales, medical and surgical retina system sales, partially offset by a decrease in surgical retina probe sales. Total product revenue from the Cyclo G6 product family was $3.3 million, essentially flat year-over-year. Other revenue increased $0.2 million to $2.2 million in Q2 2025 compared to $2.0 million in Q2 2024, driven primarily by an increase in service revenue. Gross profit in Q2 2025 was $4.7 million or a 34.5% gross margin, a decrease of $0.4 million compared to $5.1 million, or a 40.7% gross margin, in Q2 2024, driven primarily by an increase in overall manufacturing costs, product mix weighing toward capital system sales and geographic mix weighting toward international sales, partially offset by increases in ASPs. Operating expenses were $5.6 million in Q2 2025, a decrease of $2.2 million, or 28% compared to $7.8 million in Q2 2024, due mainly to expense reduction measures taken in late 2024. Net loss was $1.0 million or $0.06 per share for Q2 2025, compared to a net loss of $2.7 million, or $0.16 per share, in the same period of the prior year. Non-GAAP adjusted EBITDA for Q2 2025 was $21 thousand, an improvement of $1.7 million, compared to Non-GAAP adjusted EBITDA loss of $1.7 million for Q2 2024. Cash and cash equivalents as of June 28, 2025 were $6.8 million, a reduction of $0.4 million in the quarter. 2025 Financial OutlookThe Company plans to achieve cash flow breakeven and positive adjusted EBITDA in 2025 on revenue generation consistent with 2024. Webcast and Conference Call InformationIridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com or by dialing +1-888-596-4144 and providing passcode: 2197032 followed by pressing #. About Iridex Corporation Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com. MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions.  © 2025 Iridex Corporation.  All rights reserved. Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, value-maximizing transactions, demand for and utilization of the Company's products and results and expected sales volumes. The Company can provide no assurance that it will complete any value-maximizing transactions on behalf of its stockholders. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks further described in the “Risk Factors” section of Iridex’s most recent Annual Report on Form 10-K, as well as in Iridex’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Use of Non-GAAP Financial InformationThis press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Management evaluates and makes operating decisions using various performance measures. In addition to Iridex’s GAAP results, we consider Adjusted EBITDA. This non-GAAP result should not be considered as an alternative to net income, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present this non-GAAP result because management considers it to be an important supplemental measure of Iridex’s performance and refers to such measure when analyzing Iridex’s strategy and operations. In calculating the above non-GAAP result: Adjusted EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Adjusted EBITDA exclude from their GAAP equivalents items listed below; Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Iridex.Severance-related expenses. We excluded from our non-GAAP results the expenses related to restructuring events, partially offset by reversals of previously recognized severance expenses in subsequent periods. These expenses are unrelated to our ongoing operations, vary in size and frequency and are subject to significant fluctuations from period to period due to varying levels of restructuring activity. We believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.Nasdaq listing requirements compliance plan expenses. We excluded from our non-GAAP results the expenses related to plans for regaining compliance with the Nasdaq listing requirements. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies. Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items. A detailed reconciliation between Iridex’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Iridex’s other reports filed with or furnished to the SEC. Investor Relations ContactPhilip TaylorGilmartin Groupinvestors@iridex.com       IRIDEX CorporationCondensed Consolidated Statements of Operations(In thousands, except per share data)(Unaudited)       Three Months Ended  Six Months Ended  June 28, 2025  June 29, 2024  June 28, 2025  June 29, 2024 Total revenues$13,571  $12,631  $25,467  $24,392 Cost of revenues 8,889   7,496   15,730   14,799 Gross profit 4,682   5,135   9,737   9,593 Operating expenses:           Research and development 871   1,501   1,747   3,037 Sales and marketing 2,535   3,487   4,988   7,233 General and administrative 2,216   2,785   4,147   5,253 Total operating expenses 5,622   7,773   10,882   15,523 Loss from operations (940)  (2,638)  (1,145)  (5,930)Other expense, net (33)  (22)  (1,502)  (156)Loss from operations before provision for income taxes (973)  (2,660)  (2,647)  (6,086)Provision for income taxes 21   19   33   57 Net loss$(994) $(2,679) $(2,680) $(6,143)Net loss per share:           Basic$(0.06) $(0.16) $(0.16) $(0.38)Diluted$(0.06) $(0.16) $(0.16) $(0.38)Weighted average shares used in computing net loss per common share:           Basic 16,793   16,287   16,760   16,270 Diluted 16,793   16,287   16,760   16,270                  IRIDEX CorporationCondensed Consolidated Balance Sheets(In thousands)       June 28, 2025  December 28, 2024 ASSETS     Current assets:     Cash and cash equivalents$6,778  $2,387 Accounts receivable, net 10,030   8,394 Inventories 8,435   10,817 Prepaid expenses and other current assets 1,625   1,964 Total current assets 26,868   23,562 Property and equipment, net 40   115 Intangible assets, net 1,144   1,307 Goodwill 965   965 Operating lease right-of-use assets, net 1,295   1,792 Other long-term assets 1,273   1,394 Total assets$31,585  $29,135 LIABILITIES AND STOCKHOLDERS’ EQUITY     Current liabilities:     Accounts payable$5,749  $7,594 Accrued compensation 1,861   1,672 Accrued expenses 584   477 Convertible note payable, current -   1,734 Other current liabilities 2,101   1,812 Deferred revenue, current 2,269   2,176 Operating lease liabilities, current 1,145   1,094 Total current liabilities 13,709   16,559 Long-term liabilities:     Deferred revenue 7,587   8,350 Operating lease liabilities 248   811 Convertible note payable 3,675   1,004 Other long-term liabilities 307   314 Total liabilities 25,526   27,038 Stockholders’ equity:     Series B convertible preferred stock 6,000   - Common stock 174   174 Additional paid-in capital 90,587   89,881 Accumulated other comprehensive (loss) income (13)  51 Accumulated deficit (90,689)  (88,009)Total stockholders’ equity 6,059   2,097 Total liabilities and stockholders’ equity$31,585  $29,135        IRIDEX CorporationReconciliation of GAAP Net Loss to Adjusted EBITDA(In thousands)       Three Months Ended  Six Months Ended  June 28, 2025  June 29, 2024  June 28, 2025  June 29, 2024 Reconciliation of GAAP net loss to Adjusted EBITDA(a)           GAAP net loss$(994) $(2,679) $(2,680) $(6,143)            Interest income (14)  -   (21)  (8)Other expense 48   23   1,524   164 Provision for income taxes 21   19   33   57 Nasdaq listing compliance 152   -   152   - Depreciation and amortization 378   369   759   772 Stock-based compensation 257   419   470   813 Severance related expense (for head count reduction) 173   161   199   189 Adjusted EBITDA$21  $(1,688) $436  $(4,156) (a)Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share- based compensation, as well as certain non-GAAP adjustments.

Related News